Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPS

被引：0
|
作者：
Sawada, Ryo
Kawachi, Hayato
Yamada, Tadaaki
Tamiya, Motohiro
Negi, Yoshiki
Goto, Yasuhiro
Nakao, Akira
Shiotsu, Shinsuke
Takeda, Takayuki
Okada, Asuka
Harada, Taishi
Date, Koji
Chihara, Yusuke
Hasegawa, Isao
Kijima, Takashi
Takayama, Koichi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3730
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3730
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%
    Toyota, Y.
    Hata, T.
    Yamada, T.
    Goto, Y.
    Kijima, T.
    Watanabe, S.
    Furuya, N.
    Oba, T.
    Ikoma, T.
    Nakao, A.
    Tanimura, K.
    Taniguchi, H.
    Yoshimura, A.
    Fukui, T.
    Murata, D.
    Kaira, K.
    Shiotsu, S.
    Hibino, M.
    Okada, A.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2024, 35
  • [2] Dramatic Metabolic Response to Dual ICI With Chemotherapy in Low PD-L1 NSCLC Case
    Kumasa, Toshikazu
    Nigi, Akina
    Iwamoto, Keisuke
    Itani, Hidetoshi
    Kondou, Shigeto
    RESPIROLOGY CASE REPORTS, 2025, 13 (03):
  • [3] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [4] PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    Ardizzoni, Andrea
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [5] Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)
    Moore, M.
    Hall, R.
    Mcloughlin, E.
    Melson, J.
    Horton, B.
    Mills, A.
    Gentzler, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S738 - S738
  • [6] Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
    Takei, Shota
    Kawachi, Hayato
    Yamada, Tadaaki
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Tanimura, Keiko
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Tamiya, Nobuyo
    Katayama, Yuki
    Nishioka, Naoya
    Morimoto, Kenji
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kijima, Takashi
    Takayama, Koichi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients
    Wu, Bing
    Sun, Congcong
    Sun, Xiaoqin
    Li, Xue
    MEDICINE, 2022, 101 (36) : E30532
  • [8] Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.
    Fidler, Mary J.
    Villaflor, Victoria Meucci
    Rao, Amol
    Halmos, Balazs
    Bertino, Erin Marie
    Osarogiagbon, Raymond U.
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [10] PD-L1 in NSCLC cytology
    Kovacevic, M.
    Kern, I.
    Gabric, S.
    ANNALS OF ONCOLOGY, 2017, 28
12345